Skip to content
Search

Latest Stories

PDA investigates Boots pharmacists' pension entitlement concerns

PDA investigates Boots pharmacists' pension entitlement concerns

WBA recently moved Boots pension scheme to L&G in a £4.8 billion deal

The Pharmacists’ Defence Association (PDA) is probing major concerns arising from Boots' communications to pharmacists regarding the company's recently announced pension arrangements.


In November, Walgreens Boots Alliance (WBA), the parent company of Boots, transferred the Boots employees' pension scheme to the financial service provider Legal and General (L&G) in a £4.8 billion deal.

Boots notified staff that terms allowing an unreduced pension from age 60 have ceased immediately, following its agreement with L&G.

The PDA highlighted member concerns regarding Boots management's announcement that an unreduced pension from the age of 60 is a discretionary benefit and not guaranteed under the Boots Pension Scheme (BPS), contrary to some members' assumptions.

On December 7, the PDA communicated with affected members—those possessing pension benefits in the BPS, a final salary scheme closed to new entrants in 2010—explaining that the winding up of closed final salary schemes and securing benefits through an insurance policy is a standard procedure.

"Discretionary benefits are not protected unless explicitly included in the rules during the commencement of the winding-up process and buy-in," the PDA wrote.

PDA Union National Officer Paul Moloney said that his team has been evaluating various pieces of information, with a particular focus on the Trust Deed and Rules, which are deemed the definitive documents.

Moloney emphasised that these documents do describe the normal retirement age as 65. “However, we have also seen individual benefit statements from those members kind enough to send them to us. There is no doubt these communicate that a full pension is payable at 60,” he added.

"No mention is made that this is solely at the discretion of the trustees, and importantly, there is no indication that individuals should not rely on this arrangement still being in place upon their retirement,” he added.

Moloney said, "If benefit statements had included words to this effect, we would reluctantly have concluded that nothing could be done to safeguard the unreduced pension at 60. However, based on our examination, such language is absent."

"Our considered view, emphasising the information available to date, suggests a potential matter for resolution by the Pensions Ombudsman.”

However, the PDA advised members against taking additional steps, such as making a claim, pending further investigations by the PDA to determine whether the evidence supports the company's position.

"If not available, we will guide members on the steps to utilise the disputes procedure before filing complaints with the Ombudsman,” Moloney said in the letter.

The PDA plans to provide members with an update by the end of next week.

Boots and the Trustees of the Boots Pension Scheme announced an insurance transaction for increased certainty and security, according to the company.

“In the customary review, various pension options previously at the Trustee's discretion were assessed. Insured options, like death benefits for eligible dependants, were retained, while discretionary choices such as enhanced early retirement were discontinued,” Boots added.

In November, Boots closed three additional stores as part of its ongoing initiative to shutter 300 stores across the UK in the next 12 months.

More For You

GPhC Updates Pharmacy Education Guidance to Promote Sustainability

Pharmacies and registrants encouraged to adopt sustainable practices

gettyimages

GPhC updates education guidance to foster ‘greener’ thinking among pharmacists


The General Pharmaceutical Council (GPhC) has updated its guidance for the education and training of pharmacists and pharmacist independent prescribers to integrate environmentally sustainable practices into their curriculums.

Keep ReadingShow less
India Cracks Down on Unapproved Tapentadol-Carisoprodol Drug Exports

Tapentadol and carisoprodol combinations are potentially dangerous drugs

gettyimages

India bans export of unapproved tapentadol-carisoprodol drugs

The Union Health Ministry has taken immediate actionagainst a Mumbai-based pharmaceutical manufacturerfollowing reports of unapproved drug combinations containing Tapentadol and Carisoprodol being exported to certain West African countries.

Although Tapentadol and Carisoprodol are individually approved by Central Drugs Standard Control Organization (CDSCO) in India, their combination has not yet received approval.

Keep ReadingShow less
Infant formula: Food, diet and obesity committee welcomes CMA proposals, demands action on processed foods
CMA study shows that parents could save around £300 a year by switching to a lower priced infant formula brand (gettyimages)

Infant formula: CMA calls for stronger labelling and advertising rules

All infant formula brands should be displayed together and separately from other formula milks in stores to enable quick and easy price comparisons – suggests CMA 

The Competition and Marketing Authority (CMA) has recommended the governments of the four UK nations to strengthen advertising and labelling rules of infant formula to help parents make informed decisions and save money.

This follows a CMA study on infant formula and follow-on milks, which found that a combination of factors was leading to poor outcomes for parents.

Keep ReadingShow less
CPCF negotiations: CPE working to secure the best outcomes for the sector
Pharmacy sector demands urgent resolution of CPCF negotiations (gettyimages)

CPCF Negotiations: CPE unable to share details until official announcement

Acknowledging the sector's urgent need to resolve CPCF negotiations, CPE reiterates its commitment to securing the best possible outcome

Community Pharmacy England (CPE) has provided an update on the ongoing 2024/25 and 2025/26 Community Pharmacy Contractual Framework (CPCF) negotiations with the Department of Health and Social Care (DHSC) and NHS England.

“The Negotiating Team are continuing in-depth negotiations with DHSC and NHS England,” the Committee said, adding that they are focused on securing the “best outcomes” for pharmacy owners.

Keep ReadingShow less
David Thomas Steps In as NPA’s New Wales Representative
Five NPA members are contesting for the remaining position in England (gettyimages)

NPA board update: David Thomas succeeds Raj Aggarwal OBE

Five NPA members are contesting for the remaining position in England

David Thomas, owner of LT Chemists in Newport, will replace Raj Aggarwal OBE as the next National Pharmacy Association (NPA) board member for Wales, following an uncontested election this month.

Following the conclusion of a nomination process last week, Baldev Bange, Aisling O’Brien, Sehar Shahid, and Sanjay Ganvir have been re-elected to the Board, representing areas of England and Scotland, according to a statement from NPA.

Keep ReadingShow less